Real-World Study Shows Inotuzumab Ozogamicin Achieves 57% Remission Rate in Relapsed/Refractory B-ALL Despite Dose Modifications
核心洞察
A retrospective study of 49 patients with relapsed/refractory B-cell acute lymphoblastic leukemia (搜索) treated with inotuzumab ozogamicin achieved a 57.14% complete remission rate, with 71.4% of responders reaching minimal residual disease-negative status.
The study demonstrated reasonable efficacy even when patients received reduced doses due to financial constraints, with median doses of 1.72 mg/m²/cycle among responders versus 1.54 mg/m²/cycle among non-responders.
Hepatic sinusoidal obstruction syndrome (搜索) occurred in 20.4% of patients overall, with 50% of transplant recipients developing this complication despite prophylactic measures.
A new real-world study provides encouraging evidence that inotuzumab ozogamicin (InO) can achieve meaningful remission rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (搜索) (R/R B-ALL (搜索)), even when administered at reduced doses due to financial constraints. The retrospective analysis, published in Blood Cancer Journal, offers crucial insights into the practical application of this antibody-drug conjugate outside of clinical trial settings.
Study Design and Patient Population
Researchers analyzed data from 49 patients with R/R B-ALL (搜索) treated at their center between January 2020 and December 2024. The cohort had a median age of 24 years (range 6-68), with 40 patients receiving treatment for relapsed disease and 9 for refractory disease. Cytogenetic analysis was available for 46 patients, revealing that 6 had Philadelphia chromosome positive B-ALL (搜索).
Due to cost considerations, the study employed flexible dosing strategies. Twenty-five patients received fixed doses of 1 mg vials on days 1, 8, and 15, while 2 patients received doses on days 1 and 15 only. The remaining 22 patients received standard body surface area-based dosing. The median dose among responders was 1.72 mg/m²/cycle compared to 1.54 mg/m²/cycle among non-responders (p=0.42).
Efficacy Outcomes
The study achieved a complete remission rate of 57.14% (28 patients), with 71.4% of responders (20 patients) reaching minimal residual disease-negative status. Among the responders, 67.8% (19 patients) proceeded to consolidative therapy with allogeneic stem cell transplant (18 patients) or CAR-T cell therapy (1 patient). The median time from last InO dose to transplant was 45 days (range 30-120).
CD22 (搜索) expression analysis was available for 44 patients, showing median expression of 98.3% among responders versus 94.92% among non-responders (p=0.46), suggesting that CD22 expression levels did not significantly predict treatment response.
Safety Profile and Complications
Hepatic sinusoidal obstruction syndrome (搜索) (SOS (搜索)) emerged as a significant concern, occurring in 10 of 49 patients (20.4%). Notably, 9 of these cases (50% of the transplant cohort) developed post-transplant despite prophylactic ursodiol use. Eight patients experienced severe or very severe SOS according to EBMT criteria, though 5 patients achieved resolution with a median overall survival of 14 months post-recovery.
The study found no statistically significant correlation between SOS (搜索) occurrence and the number of InO doses (p=0.42), cumulative dose (p=0.42), or time interval between last dose and transplant (p=0.47). Patients who developed severe SOS received a median dose of 1.79 mg/m²/cycle compared to 1.61 mg/m²/cycle in those who did not develop SOS.
Febrile neutropenia (搜索) occurred in 15 patients (30.6%), representing a manageable toxicity profile consistent with previous reports.
Survival Outcomes
The one-year overall survival for the entire cohort was 51.7% ± 8.1%, with event-free survival of 32.4% ± 8%. Patients who underwent transplant or CAR-T therapy demonstrated superior outcomes with a one-year overall survival of 68.4% ± 10.7%, compared to 42.3% ± 20.6% for patients in remission who did not receive consolidative therapy (log rank p=0.129). The median follow-up for survivors in the transplant/CAR-T cohort was 20.1 months.
Comparison with Previous Studies
The findings align with broader real-world evidence from the Center for International Blood and Marrow Transplant Research, which reported SOS (搜索) incidence of 14% within 100 days post-transplant, rising to 18% in R/R ALL patients. Research by Senapati et al. demonstrated that fractionated InO dosing schedules combined with less hepatotoxic chemotherapy can reduce SOS rates to 9.8% overall and 17.3% among transplant recipients, compared to historical rates of 20-30% with non-fractionated, higher-dose regimens.
Clinical Implications
The study authors conclude that InO salvage therapy in R/R B-ALL (搜索) achieves reasonable remission rates even with dose modifications, enabling subsequent curative therapies in this challenging patient population. However, they emphasize the need for strategies to reduce post-transplant SOS (搜索) rates and prevent post-transplant relapses.
The research suggests that fractionated InO dosing combined with less hepatotoxic chemotherapy may mitigate peak calicheamicin exposure and endothelial injury, potentially reducing SOS (搜索) risk while maintaining antileukemic efficacy. The authors recommend exploring fractionated InO approaches, preferably as first salvage therapy, to optimize the risk-benefit profile in this vulnerable patient population.